Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. WEAV
WEAV logo

WEAV Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Weave Communications Inc (WEAV) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
5.470
1 Day change
2.63%
52 Week Range
11.320
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Weave Communications Inc (WEAV) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 to invest. Despite some positive growth trends in revenue and gross margin, the company's declining net income and EPS, coupled with insider selling and lack of strong trading signals, make it less compelling as a long-term investment right now. The stock's technical indicators and options data also do not suggest a strong bullish sentiment.

Technical Analysis

The MACD is positive and expanding, indicating a potential upward momentum. However, the RSI is in the neutral zone, and moving averages are converging, signaling no clear trend. The stock is trading near its resistance levels (R1: 5.296, R2: 5.498), which could limit further upside in the short term.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low put-call ratios indicate a lack of bearish sentiment, but the low overall options volume suggests limited interest in the stock.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
9

Positive Catalysts

  • Revenue growth of 17.05% YoY in Q4 2025 and gross margin improvement to 72.66% are positive indicators of operational efficiency. Analysts highlight AI and specialty medical as potential growth drivers for FY26.

Neutral/Negative Catalysts

  • Net income dropped by -72.46% YoY, and EPS declined by -77.78% YoY in Q4 2025, indicating profitability challenges. Insider selling has increased by 108.69% in the last month, which could signal a lack of confidence in the stock's near-term performance. Additionally, no recent news or significant hedge fund activity supports a bullish case.

Financial Performance

In Q4 2025, revenue increased to $63.4M (up 17.05% YoY), but net income dropped to -$1.85M (-72.46% YoY), and EPS fell to -0.02 (-77.78% YoY). Gross margin improved slightly to 72.66% (up 0.80% YoY), showing operational efficiency but not enough to offset profitability concerns.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have lowered price targets recently (Stifel: $9 from $11, Piper Sandler: $8 from $12) but maintain Buy/Overweight ratings. This indicates cautious optimism but reflects concerns about decelerating growth and profitability challenges.

Wall Street analysts forecast WEAV stock price to rise
4 Analyst Rating
Wall Street analysts forecast WEAV stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.330
sliders
Low
8
Averages
10.25
High
12
Current: 5.330
sliders
Low
8
Averages
10.25
High
12
Stifel
J. Parker Lane
Buy
downgrade
$11 -> $9
AI Analysis
2026-02-20
Reason
Stifel
J. Parker Lane
Price Target
$11 -> $9
AI Analysis
2026-02-20
downgrade
Buy
Reason
Stifel analyst J. Parker Lane lowered the firm's price target on Weave to $9 from $11 and keeps a Buy rating on the shares.
Piper Sandler
Overweight -> NULL
downgrade
$12 -> $8
2026-02-20
Reason
Piper Sandler
Price Target
$12 -> $8
2026-02-20
downgrade
Overweight -> NULL
Reason
Piper Sandler lowered the firm's price target on Weave to $8 from $12 and keeps an Overweight rating on the shares. The firm notes the company posted another quarter of 17% year-over-year growth, driven by payments, strong location additions, and the recent TrueLark acquisition. FY26 top-line growth guidance of 14.8% year-over-year came in roughly in-line with consensus expectations and implies a deceleration from the 17.0% growth in FY25, while operating income guidance implies 190 bps of operating margin expansion in the coming year. Looking ahead, Piper expects AI and specialty medical to be the biggest growth drivers in FY26.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for WEAV
Unlock Now

People Also Watch